The goal of most glaucoma treatments is to lower eye pressure more effectively or more safely for longer periods of time.
A new molecular class of drugs, rho kinase (ROCK) inhibitors, is in development for the treatment of glaucoma patients. With minimal systemic side effects and tolerable ocular side effects, ROCK inhibitors have no contraindications - thus offering doctors and patients a necessary treatment option with convenient, once-a-day dosing.
Learn more about how this class fits into the timeline of advances in glaucoma treatment, and the potential that ROCK inhibitors may hold.
Read the Whitepaper now
Today, the clade 2b outbreak has reached alarming proportions, with over 94,000 confirmed cases reported across 117 countries, including significant numbers in the U.S. and Brazil, and up to 103 deaths. The virus has been found to affect younger men who have sex with men, who are linked to high rates of HIV co-infection.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen